Azitra Inc
Harnessing the microbiome to treat skin disease.
Harnessing the microbiome to treat skin disease.
Azitra Inc is a biotechnology startup founded in 2014 with a focus on harnessing the power of the microbiome to treat skin disease. The company has established itself as a preclinical stage biotechnology firm, leveraging the expertise of scientists from Yale University and collaborating with leading experts in dermatology, microbiology, and genetic engineering. Azitra is dedicated to advancing its programs in atopic dermatitis and targeted orphan indications. The company's last investment of $5.00MPost-IPO Equity was received on 13 February 2024, marking a milestone in its growth trajectory. With its headquarters in the United States, Azitra is positioning itself as a promising player in the biotechnology, consumer goods, and healthcare sectors. For more information, visit www.azitrainc.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $10.00M | - | 23 Jul 2024 | |
| Post-IPO Equity | $5.00M | - | 13 Feb 2024 | |
| Series B | $17.00M | 3 |
|
15 Oct 2020 |
| Series A | $14.00M | 4 |
|
15 Oct 2019 |
| Grant | $719.70K | 1 |
|
09 Apr 2019 |
No recent news or press coverage available for Azitra Inc.
We care about your data, and we'd love to use cookies make your experience better.
